Evidence for a role of advanced glycation end products in atrial fibrillation

International Journal of Cardiology, 06/12/2012

Advanced glycation end–products (AGEs) and sRAGE plasma levels were higher in patients with AF, independently of diabetes mellitus, and they positively correlated with atrial dimensions, indicating a role for the AGE–RAGE axis in the arrhythmogenic structural atrial remodelling.

Methods

  • Ninety–seven consecutive outpatients were included in this transversal study.
  • Fifty–nine patients were in sinus rhythm (SR) and 38 in permanent AF.
  • Plasma fluorescent AGEs and soluble RAGE (sRAGE) were measured and comparisons between patients with and without AF were performed.
  • A multivariate logistic regression analysis was made to define the independent factors associated with AF.

Results

  • Fluorescent AGEs and sRAGE were higher in AF group (74.9±25.6 vs. 61.8±20.1a.u. for fluorescent AGEs, p=0.006; 1714.2±1105.5 vs. 996.1±820.7pg/mL for sRAGE, p=0.001).
  • These differences were specially marked in non–diabetic patients.
  • Both AGEs and sRAGE directly correlated with left atrial dimensions (r=0.496; r=0.536 for atrial area and r=0.491; r=0.511 for atrial volume, for fluorescent AGEs and sRAGE, respectively, p<0.001).
  • In a multivariate analysis, fluorescent AGEs and sRAGE resulted as markers of AF independent of left atrial distension, diabetes and other confounding variables.

Print Article Summary Cat 2 CME Report